Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings Inc (ASRT) is a pharmaceutical innovator specializing in neurology and specialty medicines, offering investors comprehensive news coverage through this dedicated hub. Access real-time updates on FDA-approved therapies, strategic partnerships, and financial developments shaping this dynamic healthcare company.
This resource provides verified press releases and analysis-free announcements covering earnings reports, product launches, and regulatory milestones. Track ASRT's progress in neurology treatments and oncology initiatives like Rolvedon through primary source documentation.
Key updates include acquisition activities, licensing agreements, and commercial strategy developments. Investors gain direct access to the company's official communications regarding market expansion, payor contracting progress, and distribution network enhancements.
Bookmark this page for unfiltered access to Assertio's latest developments in specialty pharmaceuticals. Monitor their focused approach to neurological care and orphan drug commercialization through timely, regulation-compliant disclosures.
Assertio Holdings (NASDAQ: ASRT) presented groundbreaking real-world study data for SYMPAZAN® (clobazam) Oral Film at the 150th Annual Meeting of the American Neurological Association. The study, involving 181 epilepsy patients including 29 with Lennox-Gastaut Syndrome (LGS), marks the first real-world evidence of how the medicine is used in clinical practice.
The research revealed that LGS patients were typically younger (13.6 years vs. 21.1 years in the epilepsy group) and more frequently switched from other clobazam formulations. SYMPAZAN, the only FDA-approved oral film formulation of clobazam, is specifically designed for patients two years and older who have difficulty swallowing tablets or liquids.
Assertio Holdings (Nasdaq: ASRT) will present new data from a real-world evidence study of SYMPAZAN at the 150th Annual Meeting of the American Neurological Association (ANA2025). SYMPAZAN is the only FDA-approved oral film formulation of clobazam for treating seizures associated with Lennox-Gastaut syndrome in patients aged two and older.
The presentation will take place on September 15, 2025, from 12:00 – 7:30 p.m. ET at the Baltimore Marriott Waterfront. The abstract titled "Real-World Evidence Study of Patients with Lennox-Gastaut Syndrome Taking Clobazam Oral Soluble Film" will focus on patient demographics, medications, and comorbidities. Detailed study findings will be released on the presentation day, following ANA2025 embargo policy.
Assertio Holdings (NASDAQ: ASRT) announced its participation in two upcoming investor conferences in New York City during September 2025. The management team will host investor meetings at the HC Wainwright Conference on September 10, 2025, at the Lotte New York Palace Hotel, and at the Lake Street Capital Markets BIG9 Conference on September 11, 2025, at the Yale Club New York City.
Interested investors can register and request meetings through their respective HC Wainwright or Lake Street representatives.
Assertio Holdings (NASDAQ: ASRT) reported Q2 2025 financial results with total net product sales of $28.8 million, down from $30.7 million in Q2 2024. The company's cash position strengthened to $98.2 million, up from $87.3 million in Q1 2025.
Key product performance included Rolvedon sales of $16.1 million (up from $15.1 million), Sympazan sales of $3.2 million (up from $2.7 million), and Indocin sales of $3.0 million (down from $6.9 million). The company reported a GAAP net loss of $16.4 million but achieved Adjusted EBITDA of $5.6 million.
Assertio narrowed its 2025 guidance, projecting net product sales of $108.0-118.0 million and adjusted EBITDA of $11.0-19.0 million. The company continues its transformation strategy, including streamlining operations and focusing on core growth assets.
Assertio Holdings (NASDAQ:ASRT) has scheduled its second quarter 2025 financial results announcement for Monday, August 11, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss Q2 results and provide updates on 2025 strategic plans.
Investors can access the webcast through Assertio's investor relations website, with a recommended connection time of 10 minutes before the start. For telephone participants, the dial-in number is +1-646-307-1963 with call ID 3278948. A replay will be available approximately two hours after the call on the company's investor website.
Assertio Holdings (NASDAQ: ASRT) has announced that its CEO, Brendan O'Grady, will participate in the Alliance Global Partners Healthcare Company Showcase on May 21, 2025. The event will feature a fireside chat that will be webcast live at 11:20 a.m. ET. Interested participants can access the virtual presentation through registration on the provided Zoom link or by visiting the Events & Presentations section of Assertio's investor relations website.
Assertio Holdings (NASDAQ: ASRT) reported Q1 2025 financial results with total net product sales of $26.0 million, down from $31.9 million in Q1 2024. The company posted a net loss of $13.5 million ($0.14 per share) compared to a loss of $4.5 million ($0.05 per share) in the prior year quarter. Rolvedon sales reached $13.1 million, while Indocin contributed $5.5 million.
The company's transformation strategy focuses on reducing legal exposure, simplifying corporate structure, prioritizing growth assets, and pursuing strategic transactions. Notable achievements include settling multiple legal matters and transferring Assertio Therapeutics subsidiary to ATIH Industries. The company maintained a strong balance sheet with $87.3 million in cash and equivalents and $40.0 million in debt as of March 31, 2025.
Assertio Holdings (NASDAQ: ASRT) has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025, after market close. The company will host a live webcast conference call at 4:30 p.m. Eastern Time where management will discuss Q1 2025 results and provide updates on the company's 2025 strategic plans.
Investors can access the webcast through Assertio's investor relations website. Those preferring to join by phone can dial +1-646-307-1963 using call ID 3278948. A replay of the webcast will be available approximately two hours after the call on the company's investor website.
Assertio Holdings (Nasdaq: ASRT) has announced its participation in the upcoming iAccess Alpha Best Ideas Spring Investment Conference, scheduled for March 25-26, 2025. CEO Brendan O'Grady will lead the company's presentation on Tuesday, March 25, 2025, at 1:30 pm Eastern Time.
The conference will be held virtually, with a webcast available through the company's investor relations website. Investors attending the conference can schedule one-on-one meetings with Assertio representatives on March 26, 2025, either through their conference representative or by contacting Assertio's investor relations directly.
Assertio Holdings (NASDAQ: ASRT) reported its Q4 and full-year 2024 financial results, with Q4 net product sales of $29.6 million and full-year sales reaching $120.8 million. The company generated strong cash flows, with Q4 operating cash flow of $11.5 million and full-year operating cash flow of $26.4 million.
Q4 highlights include Rolvedon sales of $15.4 million (up $0.4M from Q3) and Indocin sales of $5.5 million (down from $5.7M in Q3). Gross margin was 61% in Q4, down from 74% in Q3, impacted by $2.9 million in inventory write-downs. The company reported an Adjusted EBITDA loss of $0.5 million for Q4.
The company ended 2024 with $100.1 million in cash and investments and $40.0 million in convertible notes debt due September 2027. Management expects 2025 to be transformational, focusing on revenue growth initiatives for Rolvedon and Sympazan while actively pursuing strategic acquisitions.
FAQ
What is the current stock price of Assertio Holdings (ASRT)?
What is the market cap of Assertio Holdings (ASRT)?
